Physician profile
Neeraj Sinha
NPI 1891745543
$3,761.67
in general payments reported to CMS, 2019-2025
17 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $854 · 2021: $267 · 2022: $196 · 2023: $830 · 2024: $955 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.68 |
| Education | $344.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,898.10 | 2020-2025 | Cresemba |
| Fisher & Paykel Healthcare INC | $488.56 | 2023 | Fisher & Paykel Healthcare |
| Outset Medical INC | $242.22 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.18 | 2024-2025 | Ofev, Jardiance |
| Medtronic Vascular, INC. | $131.19 | 2019 | |
| Mallinckrodt Hospital Products INC. | $113.88 | 2023 | Acthar |
| Abbott Laboratories | $113.43 | 2019 | |
| United Therapeutics Corporation | $105.07 | 2025 | |
| One Lambda, INC. | $100.61 | 2024 | |
| Ambu INC. | $94.63 | 2020-2021 | |
| Livanova USA, INC. | $73.79 | 2021 | |
| Boston Scientific Corporation | $71.94 | 2021-2023 | Exalt Model D |
| Eurofins Viracor, LLC | $50.65 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.27 | 2024 | Livtencity |
| Verona Pharma, INC. | $28.94 | 2025 | Ohtuvayre |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $27.21 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.